Estrella Immunopharma’s Chief Financial Officer, Jiandong Xu, reported a series of open-market purchases of the company’s common stock. On October 7, 2025, he bought 1,000 shares at $1.33 per share, bringing his direct holdings to 265,488 shares.
Earlier, on September 11, 2025, Xu purchased 100 shares at $1.04 per share. On September 22, 2025, 1,000 shares were purchased at $1.16 per share and are held by his spouse, totaling 16,700 shares in that account. The filing states Xu disclaims beneficial ownership of the spouse-held shares for Section 16 and other purposes.
Estrella Immunopharma, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the registration statement unchanged and focuses on updating the list of exhibits.
The filing itemizes corporate documents such as the amended and restated charter and bylaws, various merger and financing agreements, equity incentive plans, employment agreements, and a warrant agreement, largely incorporated by reference from earlier filings. It also includes the legal opinion from Winston & Strawn LLP, consents from current and former auditors, XBRL-related exhibits, and powers of attorney.
The amendment is signed on behalf of Estrella Immunopharma by Chief Executive Officer Cheng Liu and lists the company’s principal officers and directors, confirming their authorization of the registration statement.
Estrella Immunopharma, Inc. is registering up to 9,236,141 shares of common stock for resale by existing selling stockholders, including shares already issued, contingent “true-up” and reset shares, and shares issuable upon exercise of warrants from recent private placements. The registered resale shares represent approximately 22.0% of total common stock outstanding as of January 11, 2026, creating potential stock overhang as these holders may sell over time.
Estrella will not receive proceeds from stockholder resales under this prospectus. A significant portion of the shares was or may be issued at effective prices below recent trading levels, which may incentivize sales at market prices. The company remains a clinical-stage, loss‑making cell therapy developer focused on its lead candidate EB103 for relapsed or refractory B‑cell malignancies, with an accumulated deficit of about $36.4 million as of September 30, 2025 and a disclosed need for substantial additional funding. Estrella is controlled by Eureka Therapeutics, which holds about 60.1% of the voting power.